[
  {
    "ts": "2025-11-03T22:30:02+00:00",
    "headline": "Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates",
    "summary": "Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finance.yahoo.com/news/vertex-vrtx-q3-earnings-key-223002955.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "465d7356-ef88-35e1-92d7-31ecf8e433e5",
      "content": {
        "id": "465d7356-ef88-35e1-92d7-31ecf8e433e5",
        "contentType": "STORY",
        "title": "Vertex (VRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates",
        "description": "",
        "summary": "Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
        "pubDate": "2025-11-03T22:30:02Z",
        "displayTime": "2025-11-03T22:30:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E8QyPjKtRaOQj91uVCJHQA--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hjTg63kWHBfUb8JQmmr1kg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/8442d24e11d454aa89061259a9714d43.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-vrtx-q3-earnings-key-223002955.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-vrtx-q3-earnings-key-223002955.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T22:15:04+00:00",
    "headline": "Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates",
    "summary": "Vertex (VRTX) delivered earnings and revenue surprises of +5.49% and +1.14%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-q3-earnings-221504645.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "649c2afe-41f7-350e-9bad-c7ea016fba84",
      "content": {
        "id": "649c2afe-41f7-350e-9bad-c7ea016fba84",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Top Estimates",
        "description": "",
        "summary": "Vertex (VRTX) delivered earnings and revenue surprises of +5.49% and +1.14%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?",
        "pubDate": "2025-11-03T22:15:04Z",
        "displayTime": "2025-11-03T22:15:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/f541c90e0d995722d10914cb76a7c653",
          "originalWidth": 900,
          "originalHeight": 600,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0sIIP41M0Yl73BbPadjNMg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f541c90e0d995722d10914cb76a7c653.cf.webp",
              "width": 900,
              "height": 600,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WsNU52Eg.hsicG83rNZXgw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f541c90e0d995722d10914cb76a7c653.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-q3-earnings-221504645.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-q3-earnings-221504645.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T21:44:15+00:00",
    "headline": "Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations",
    "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $11.95 billion at the midpoint. Its non-GAAP profit of $4.80 per share was 4.9% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-nasdaq-vrtx-reports-214415023.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "80afb158-66f0-329a-99c0-4ba821404f65",
      "content": {
        "id": "80afb158-66f0-329a-99c0-4ba821404f65",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Q3 In Line With Expectations",
        "description": "",
        "summary": "Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) met Wall Streets revenue expectations in Q3 CY2025, with sales up 11% year on year to $3.08 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $11.95 billion at the midpoint. Its non-GAAP profit of $4.80 per share was 4.9% above analysts’ consensus estimates.",
        "pubDate": "2025-11-03T21:44:15Z",
        "displayTime": "2025-11-03T21:44:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VRTX Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l6Y31wu10RiElUns.3mORA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qe_uhCRKlCGgByoENi3GZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-nasdaq-vrtx-reports-214415023.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-nasdaq-vrtx-reports-214415023.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T21:11:02+00:00",
    "headline": "Vertex: Q3 Earnings Snapshot",
    "summary": "On a per-share basis, the Boston-based company said it had profit of $4.20. Earnings, adjusted for one-time gains and costs, were $4.80 per share. The results exceeded Wall Street expectations.",
    "url": "https://finance.yahoo.com/news/vertex-q3-earnings-snapshot-211102285.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "1b13e8af-9b75-361a-8403-a6413efa5123",
      "content": {
        "id": "1b13e8af-9b75-361a-8403-a6413efa5123",
        "contentType": "STORY",
        "title": "Vertex: Q3 Earnings Snapshot",
        "description": "",
        "summary": "On a per-share basis, the Boston-based company said it had profit of $4.20. Earnings, adjusted for one-time gains and costs, were $4.80 per share. The results exceeded Wall Street expectations.",
        "pubDate": "2025-11-03T21:11:02Z",
        "displayTime": "2025-11-03T21:11:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-q3-earnings-snapshot-211102285.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-q3-earnings-snapshot-211102285.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T21:02:00+00:00",
    "headline": "Vertex Reports Third Quarter 2025 Financial Results",
    "summary": "BOSTON, November 03, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.",
    "url": "https://finance.yahoo.com/news/vertex-reports-third-quarter-2025-210200926.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "461a896d-4d45-3baf-8a8c-3eea0296cf52",
      "content": {
        "id": "461a896d-4d45-3baf-8a8c-3eea0296cf52",
        "contentType": "STORY",
        "title": "Vertex Reports Third Quarter 2025 Financial Results",
        "description": "",
        "summary": "BOSTON, November 03, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance.",
        "pubDate": "2025-11-03T21:02:00Z",
        "displayTime": "2025-11-03T21:02:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/cee464266f7dad0bff2d392cb3b7bd73",
          "originalWidth": 480,
          "originalHeight": 252,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tj4MQ2sn4qRtv.7DTM0e_Q--~B/aD0yNTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cee464266f7dad0bff2d392cb3b7bd73.cf.webp",
              "width": 480,
              "height": 252,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LQzrZ921evdNXsHwMXRr1Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/cee464266f7dad0bff2d392cb3b7bd73.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-reports-third-quarter-2025-210200926.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-reports-third-quarter-2025-210200926.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T16:26:04+00:00",
    "headline": "Stock Market Today: Palantir, Vertex, and Hims & Hers Report After the Closing Bell",
    "summary": "This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Monday. This is TheStreet’s Stock Market Today for Nov. 3, 2025. You can follow the latest updates on the market ...",
    "url": "https://www.thestreet.com/markets/stock-market-today-stocks-rise-to-start-week-as-tylenol-maker-inks-48-7-billion-megadeal",
    "source": "TheStreet",
    "provider": "yfinance",
    "raw": {
      "id": "ce09188a-2655-37c7-a024-34c0c0c3ffe8",
      "content": {
        "id": "ce09188a-2655-37c7-a024-34c0c0c3ffe8",
        "contentType": "STORY",
        "title": "Stock Market Today: Palantir, Vertex, and Hims & Hers Report After the Closing Bell",
        "description": "",
        "summary": "This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Monday. This is TheStreet’s Stock Market Today for Nov. 3, 2025. You can follow the latest updates on the market ...",
        "pubDate": "2025-11-03T16:26:04Z",
        "displayTime": "2025-11-03T16:26:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/thestreet_881/3e86574a1b86110290e6ed155baff1ea",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cRXFvKp7TiCbKk3AnEkuEg--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/thestreet_881/3e86574a1b86110290e6ed155baff1ea.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ey0UjxbZGy.JHV1LJxqvKQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/thestreet_881/3e86574a1b86110290e6ed155baff1ea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TheStreet",
          "url": "https://www.thestreet.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thestreet.com/markets/stock-market-today-stocks-rise-to-start-week-as-tylenol-maker-inks-48-7-billion-megadeal",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stock-market-today-stocks-rise-162604183.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "HIMS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T15:11:00+00:00",
    "headline": "Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?",
    "summary": "CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.",
    "url": "https://finance.yahoo.com/news/crsp-stock-portfolio-pre-q3-151100297.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "1704de6a-61de-3fe7-a799-a73be4f4a507",
      "content": {
        "id": "1704de6a-61de-3fe7-a799-a73be4f4a507",
        "contentType": "STORY",
        "title": "Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?",
        "description": "",
        "summary": "CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.",
        "pubDate": "2025-11-03T15:11:00Z",
        "displayTime": "2025-11-03T15:11:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/crsp-stock-portfolio-pre-q3-151100297.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/crsp-stock-portfolio-pre-q3-151100297.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T12:37:00+00:00",
    "headline": "2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon",
    "summary": "These healthcare stocks are making strides in very important ways.",
    "url": "https://www.fool.com/investing/2025/11/03/2-healthcare-stocks-for-investors-with-a-20-year/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "8f04277a-7116-3e76-9aed-588f39f7e5fa",
      "content": {
        "id": "8f04277a-7116-3e76-9aed-588f39f7e5fa",
        "contentType": "STORY",
        "title": "2 Healthcare Stocks for Individual Investors With a 20-Year Time Horizon",
        "description": "",
        "summary": "These healthcare stocks are making strides in very important ways.",
        "pubDate": "2025-11-03T12:37:00Z",
        "displayTime": "2025-11-03T12:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/d38fcef9326aeb895f925247ddffedce",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A smiling person wearing a burgundy suit and glasses stands against a blue wall.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0vCKOHUfGfj11BU3umqTHw--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/d38fcef9326aeb895f925247ddffedce.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_BCV9H_kryQlDtESZCbQuA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/d38fcef9326aeb895f925247ddffedce.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/03/2-healthcare-stocks-for-investors-with-a-20-year/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-healthcare-stocks-individual-investors-123700266.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T07:42:54+00:00",
    "headline": "McDonald’s Earnings, Tariff Update, Musk Pay Vote: What to Watch This Week",
    "summary": "Following President Trump's return from Asia, eyes are on whether an end to the government shutdown is in sight. Meanwhile, investors will dig into earnings from McDonald’s, Palantir and a host of other companies.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-03-2025/card/mcdonald-s-earnings-tariff-update-musk-pay-vote-what-to-watch-this-week-RoN8F6Yf2gkz32oBKwYH?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "df6487af-0d38-38f5-85c6-f622488c55fe",
      "content": {
        "id": "df6487af-0d38-38f5-85c6-f622488c55fe",
        "contentType": "STORY",
        "title": "McDonald’s Earnings, Tariff Update, Musk Pay Vote: What to Watch This Week",
        "description": "",
        "summary": "Following President Trump's return from Asia, eyes are on whether an end to the government shutdown is in sight. Meanwhile, investors will dig into earnings from McDonald’s, Palantir and a host of other companies.",
        "pubDate": "2025-11-03T07:42:54Z",
        "displayTime": "2025-11-03T07:42:54Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/df6487af-0d38-38f5-85c6-f622488c55fe/mcdonald%E2%80%99s-earnings-tariff.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/d7931448f55c4ad739fd04163eccadc3",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4Aa7LUkSJqo2ocW8DI5hlA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/d7931448f55c4ad739fd04163eccadc3.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vE9eONZGUXtdI6Wa0XF7QA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/d7931448f55c4ad739fd04163eccadc3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-03-2025/card/mcdonald-s-earnings-tariff-update-musk-pay-vote-what-to-watch-this-week-RoN8F6Yf2gkz32oBKwYH?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "MCD"
            },
            {
              "symbol": "TSLA"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "SHOP"
            },
            {
              "symbol": "UBER"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "APO"
            },
            {
              "symbol": "MAR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-03T00:14:11+00:00",
    "headline": "Vertex Pharmaceuticals (VRTX): Exploring Valuation After Promising Kidney Therapy Results and Growth in New Treatments",
    "summary": "Vertex Pharmaceuticals (VRTX) is gaining attention as new clinical data for its kidney disease therapy, povetacicept, shows encouraging results. The company’s portfolio is also benefiting from steady cystic fibrosis sales and early momentum from its latest treatments. See our latest analysis for Vertex Pharmaceuticals. The excitement around Vertex’s kidney therapy news comes as share price momentum has started building again, with a 1-month share price return of 5.5% and year-to-date gains of...",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-exploring-valuation-001411495.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "0f6791e7-b678-3c61-85f2-54515733aaca",
      "content": {
        "id": "0f6791e7-b678-3c61-85f2-54515733aaca",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (VRTX): Exploring Valuation After Promising Kidney Therapy Results and Growth in New Treatments",
        "description": "",
        "summary": "Vertex Pharmaceuticals (VRTX) is gaining attention as new clinical data for its kidney disease therapy, povetacicept, shows encouraging results. The company’s portfolio is also benefiting from steady cystic fibrosis sales and early momentum from its latest treatments. See our latest analysis for Vertex Pharmaceuticals. The excitement around Vertex’s kidney therapy news comes as share price momentum has started building again, with a 1-month share price return of 5.5% and year-to-date gains of...",
        "pubDate": "2025-11-03T00:14:11Z",
        "displayTime": "2025-11-03T00:14:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-exploring-valuation-001411495.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-exploring-valuation-001411495.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]